STOCK TITAN
  1. Home
  2. News
  3. SRPT

Sarepta Therapeutics Inc Stock Price, News & Analysis

SRPT Nasdaq

Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.

Sarepta Therapeutics Inc (NASDAQ: SRPT) is a leader in precision genetic medicine, pioneering RNA-targeted therapies for rare neuromuscular and infectious diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on SRPT's scientific advancements, regulatory milestones, and strategic initiatives.

Access real-time press releases covering clinical trial developments, partnership announcements, and financial disclosures. Our curated news collection simplifies tracking SRPT's progress in bringing transformative treatments to underserved patient populations through its proprietary platform technologies.

Key updates include FDA communications regarding novel therapies, research collaborations advancing genetic medicine, and operational developments impacting SRPT's therapeutic pipeline. All content is verified through primary sources to ensure accuracy and timeliness.

Bookmark this page for streamlined access to Sarepta's latest achievements in exon-skipping therapies and gene editing innovations. Stay informed about critical developments shaping this biopharmaceutical innovator's trajectory in targeted genetic treatments.

News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT), a precision genetic medicine company focused on rare diseases, announced the granting of equity awards to 53 new employees hired in Q2 2025. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, include 22,016 stock options at an exercise price of $17.10 per share and 317,317 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments. Both awards are subject to continued employment with Sarepta. These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

[]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
News

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Rhea-AI Summary
Sarepta Therapeutics (SRPT) has reported a second death from acute liver failure in non-ambulatory Duchenne patients treated with ELEVIDYS gene therapy. In response, the company is implementing critical safety measures including: suspending ELEVIDYS shipments for non-ambulatory patients, pausing the ENVISION confirmatory trial, and developing an enhanced immunosuppressive regimen that includes sirolimus. The company is consulting with clinical experts and regulators to strengthen safety protocols. The current treatment protocol remains unchanged for ambulatory patients. Over 900 patients have been treated with ELEVIDYS to date. The safety update follows liver enzyme elevations, a known side effect of AAV-based gene therapies, with evidence suggesting an adaptive immune response mechanism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

Rhea-AI Summary
Sarepta Therapeutics announced that the FDA has granted platform technology designation to the rAAVrh74 viral vector used in SRP-9003, their investigational gene therapy for limb-girdle muscular dystrophy type 2E/R4. This designation, among the first of its kind, recognizes the technology's reproducibility and adaptability across multiple therapeutic programs. The platform technology designation allows Sarepta to leverage prior data to support future drug applications, streamlining development and review processes. SRP-9003 is designed to deliver a full-length beta-sarcoglycan transgene using the MHCK7 promoter, targeting skeletal, diaphragm, and cardiac muscle. This is particularly crucial for LGMD2E patients who often face pulmonary or cardiac complications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
fda approval
News

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

Rhea-AI Summary
Sarepta Therapeutics (NASDAQ:SRPT) announced that the UK's Medicines & Healthcare products Regulatory Agency (MHRA) has allowed continued uninterrupted dosing of ELEVIDYS in the ENVISION Phase 3 study. The study evaluates this gene therapy treatment in non-ambulatory and older ambulatory individuals with Duchenne muscular dystrophy (DMD). ELEVIDYS is a single-dose, AAV-based gene therapy designed to address DMD's genetic cause through micro-dystrophin production. The therapy is approved in the US for DMD patients aged 4 and older, both ambulatory and non-ambulatory, with the latter approved under accelerated approval pending confirmatory trials. The press release details important safety information, including potential risks such as infusion-related reactions, liver injury, immune-mediated myositis, and myocarditis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

Rhea-AI Summary
Sarepta Therapeutics (NASDAQ:SRPT) reported new results from the ENDEAVOR study of ELEVIDYS for Duchenne muscular dystrophy treatment. In cohort 6 (n=6) with 2-year-old patients, treatment demonstrated mean protein expression of 93.87% measured by western blot and 79.9% dystrophin positive fibers. Safety profile aligned with previous studies, with common side effects including nausea and vomiting. Two patients experienced elevated liver enzymes, which resolved with steroid treatment. Previously reported results from Cohort 4 (3-year-olds, n=7) showed 99.64% mean protein levels. Over 25 patients under age 4 have been treated in clinical studies. The company plans to meet with FDA next month to discuss expanding ELEVIDYS label to include younger patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
-
News

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

Rhea-AI Summary
Sarepta Therapeutics (SRPT) presented new data from Part 2 of the EMBARK study for ELEVIDYS, their approved gene therapy for Duchenne muscular dystrophy. The analysis focused on 8-9 year old patients (n=14) who received treatment after placebo in Part 1. At one year post-treatment, patients showed statistically significant improvements across key endpoints compared to controls: • 4.75 points improvement in North Star Ambulatory Assessment (P=0.0026) • 6.87 seconds better in time-to-rise from floor (P=0.0010) • 4.76 seconds improvement in 10-meter walk/run (P=0.0097) These results are particularly notable as they demonstrate functional improvements at an age when motor decline typically occurs in Duchenne patients. The two-year study data showed sustained micro-dystrophin expression from Week 12 to Week 64 in a subset of patients, with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
News

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

Rhea-AI Summary
Sarepta Therapeutics (NASDAQ:SRPT) has received approval from Japan's MHLW for ELEVIDYS, a gene therapy treatment for Duchenne muscular dystrophy (DMD). This marks the first global approval for treating patients younger than 4 years old, covering ages 3 to under 8 years. The approval is based on positive efficacy and safety data from clinical studies, including two-year results from the Phase 3 EMBARK trial, which demonstrated significantly better motor function outcomes compared to controls. Through a collaboration with Roche, Sarepta will receive up to $103.5M in milestone payments. The therapy will be commercialized in Japan by Chugai Pharmaceuticals via its Roche alliance. ELEVIDYS is a single-dose, AAV-based gene therapy designed to address DMD's genetic cause through micro-dystrophin production in skeletal muscle.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
News

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced its senior management will participate in a fireside chat at the BofA Securities Health Care Conference. The event will take place at the Encore Hotel in Las Vegas on May 14, 2025, at 8:40 a.m. PT/11:40 a.m. ET.

The presentation will be available via webcast on Sarepta's investor relations website and will remain archived for 90 days. The company maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, while developing a portfolio focused on muscle, central nervous system, and cardiac diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
News

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Rhea-AI Summary
Sarepta Therapeutics (SRPT) reported Q1 2025 financial results with total revenues of $744.9M, up 80% year-over-year. Net product revenues reached $611.5M, a 70% increase, with ELEVIDYS contributing $375.0M (180% growth) and PMO franchise at $236.5M. However, facing headwinds, Sarepta revised its 2025 revenue guidance down to $2.3-2.6B from $2.9-3.1B. The company reported a GAAP net loss of $447.5M. The quarter saw significant pipeline progress in limb-girdle muscular dystrophy programs, including advancement in SRP-9005 (LGMD2C/R5), completed enrollment in SRP-9004 (LGMD2D/R3) study, and completion of EMERGENE phase 3 trial for SRP-9003. Sarepta closed a global licensing agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical programs in muscle, CNS, and rare pulmonary disorders.

Cash position stood at $647.5M as of March 31, 2025, down from $1.5B at year-end 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.45%
Tags
earnings
News

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has scheduled its first quarter 2025 financial results announcement. The results will be released after the Nasdaq Global Market closes on Tuesday, May 6, 2025, followed by a conference call at 4:30 p.m. E.T. to discuss the quarterly performance.

The event will be accessible through a live webcast on the investor relations section of Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for accessing the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
earnings

FAQ

What is the current stock price of Sarepta Therapeutics (SRPT)?

The current stock price of Sarepta Therapeutics (SRPT) is $18.24 as of July 3, 2025.

What is the market cap of Sarepta Therapeutics (SRPT)?

The market cap of Sarepta Therapeutics (SRPT) is approximately 1.7B.
Stock SRPT logo
Sarepta Therapeutics Inc

Nasdaq:SRPT

SRPT Rankings

#1502 Ranked by Market Cap
N/A Ranked by Dividends

SRPT Stock Data

1.69B
93.93M
4.41%
92.37%
5.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE